Not all studies are created equal. Here's how the research we'll examine stacks up by evidence quality:
| Evidence Level | Study Type | Key Studies in This Analysis | Strength |
|---|---|---|---|
| Level 1 | Systematic Review / Meta-Analysis | Cochrane 2026 (cessation); BMJ meta-analysis (quitting & mental health) | Strong |
| Level 2 | National Cross-Sectional Survey | CDC NYTS 2024 (n=100,000+); NYTS PLOS Mental Health 2025 | Moderate-Strong |
| Level 3 | Cohort / Longitudinal | Systematic review of longitudinal studies (persistent vaping → future depression) | Moderate |
| Level 4 | Neurobiological / Animal | VTA-amygdala pathway study (2025); Nicotine-depression molecular docking | Mechanistic |
| Level 5 | Cross-Sectional (Single Site) | Bangladesh university study; Ontario cessation study | Hypothesis-generating |
Method Note: Cross-sectional studies (the majority of vaping-mental health research) can show association but cannot prove causation. The "chicken or egg" problem — does vaping cause depression, or do depressed individuals self-medicate with nicotine? — remains partially unresolved. However, longitudinal studies showing that persistent vaping predicts future depressive symptoms provide stronger evidence for a causal direction.
